iCamuno Biotherapeutics Ltd.

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 1
dopamine progenitor cell replacementCell therapy
Parkinson's Disease
Phase 1
Dopamine progenitor cellsCell therapy
Parkinson's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.